Oracle (ORCL): Database At Positive Inflection Point - Jefferies
- Health, tech stocks extend Wall Street record-setting rally
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
- Exclusive: Japan's TDK in talks to buy iPhone supplier InvenSense - sources
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Jefferies analyst, John DiFucci, reiterated his Buy rating on shares of Oracle (NYSE: ORCL) along with the price target of $51. The analyst expects to see a positive inflection point in ORCL's most significant business – the database.
The analyst believes the imminent release of the 12c R2 ORCL database could add 8-9% of growth to annual revenue once fully realized, or ~2-3% if all new business is PaaS. The cumulative PaaS magnitude would grow faster, outstripping the equivalent license+mtn contribution within 6 years. Additionally, this incremental growth is not in his estimates.
Shares of Oracle closed at $41.26 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL): Earnings Preview, Checks Show Strong Cloud Revenue - Jefferies
- MKM Partners Raises Price Target on Broadcom Ltd. (AVGO) to $207 Following 4Q Beat
- Jefferies Raises Price Target on NeuroDerm (NDRM) to $42
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!